Review
Neurosciences
Shrujna Patel, Brooke A. Keating, Russell C. Dale
Summary: Mental health and neurodevelopmental disorders are common and complex conditions that affect wellbeing. There is evidence suggesting a role of maternal inflammation in these disorders, and it is now known that commonly used psychiatric drugs have anti-inflammatory properties. This review summarizes the human evidence of the anti-inflammatory mechanisms of psychiatric drugs and highlights the potential therapeutic implications.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Psychiatry
Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimoto
Summary: This study compared the effect of oral aripiprazole and aripiprazole once-monthly (AOM) on autonomic nervous system activity in patients with schizophrenia. The results showed that AOM may have fewer adverse effects, such as sympathetic nervous dysfunction, compared to oral aripiprazole.
Article
Immunology
Dalia A. Nawwar, Hala F. Zaki, Rabab H. Sayed
Summary: This study investigates the effects of aripiprazole and sertindole on the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in ketamine-induced schizophrenia in rats. Both aripiprazole and sertindole significantly ameliorated ketamine-induced schizophrenic-like behavior and oxidative stress, while activating the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways. These findings suggest that targeting these signaling pathways may offer a new therapeutic approach for treating schizophrenia in humans.
INFLAMMOPHARMACOLOGY
(2022)
Article
Neurosciences
Vjekoslav Peitl, Mario Stefanovic, Ivona Orlovic, Jelena Culej, Ana Rendulic, Krunoslav Matesic, Dalibor Karlovic
Summary: Aripiprazole long-acting injectable showed short-term positive impact on cognitive functions in recent onset schizophrenia patients, with associations with COMT, MTHFR, and SERT gene polymorphisms, particularly in terms of attention and executive functioning.
PSYCHOPHARMACOLOGY
(2021)
Article
Clinical Neurology
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S. Bell Lynum, Sanjeda R. Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R. Saklad
Summary: Aripiprazole 2-month ready-to-use 960 mg and Aripiprazole lauroxil 1064 mg are both long-acting injectable formulations used for the treatment of schizophrenia. Comparing the drug concentrations, both formulations maintain therapeutic levels over the 2-month dosing interval.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Pharmacology & Pharmacy
Lisa Alina Kneller, Pablo Zubiaur, Dora Koller, Francisco Abad-Santos, Georg Hempel
Summary: Physiologically based pharmacokinetic models accurately predict the pharmacokinetics of aripiprazole based on CYP2D6 phenotypes, allowing for personalized dose adjustments. For poor metabolizers, daily doses should be adjusted to a maximum recommended dose of 10 mg.
CLINICAL PHARMACOKINETICS
(2021)
Article
Psychiatry
Matthew Atkins, David Taylor, Ana Catalan, Neville Desouza, Edward Chesney, Thomas J. Reilly, Irina Baburina, Mary Rose Hilaire, Luiz Dratcu, Robert Harland, Salvatore J. Salamone, Philip McGuire
Summary: This study introduced a new point of care test for measuring the concentration of aripiprazole in capillary blood. The results showed that the test provided accurate and reliable measurements compared to the standard laboratory method.
BRITISH JOURNAL OF PSYCHIATRY
(2023)
Article
Biochemistry & Molecular Biology
Zofia Rogoz, Kinga Kaminska, Marta Anna Lech, Elzbieta Lorenc-Koci
Summary: The study compared the efficacy of aripiprazole and N-acetylcysteine in treating negative symptoms and cognitive disorders in rats, and found that these drugs differently modulated the levels of BDNF in the brain.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Medicinal
Ashish A. Gawai, Kailash R. Biyani, Sanjib Das, Ganesh G. Tapadiya, Santosh N. Mokale, Sachin A. Dhawale
Summary: This study synthesized a series of new compounds for the treatment of schizophrenia. The molecular docking approach was used to screen for potential pharmacological activity. Experimental and analytical data showed that compounds 4b, 4c, 4e, 4g, and 4i demonstrated promising pharmacological action in preliminary studies.
CURRENT COMPUTER-AIDED DRUG DESIGN
(2023)
Article
Clinical Neurology
Iveta Vojtechova, Klara Tuckova, Radomir Juza, Ales Stuchlik, Eduard Kelemen, Jan Korabecny, Ondrej Soukup, Tomas Petrasek
Summary: This study examined the efficacy of two experimental compounds (K1697 and K1700) and the reference drug aripiprazole in two rat models of schizophrenia. The results showed that K1700 had comparable or greater efficacy than aripiprazole in the amphetamine model, while it was less efficient than aripiprazole in the dizocilpine model. These findings highlight the differences in responsiveness to pharmacotherapy between the two schizophrenia models.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2023)
Article
Medicine, Research & Experimental
Ahmed M. Abdelfattah, Sally A. Abuelezz, Nevien Hendawy, Eman A. Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khalil
Summary: This study tested the effects of antipsychotic drugs amisulpride and/or aripiprazole on the Sonic hedgehog (Shh)-pathway, cognitive functions, and neurogenesis in a rat model of schizophrenia. The results showed that social isolation led to cognitive dysfunction, disorganized Shh-pathway proteins, and increased glial fibrillary acidic protein (GFAP)-stained astrocytes. However, treatment with these drugs reversed these changes, increasing Shh, transmembrane patched-1 and smoothened, glioma-associated-oncogene (GLI)-1 levels, dopamine-1 receptors and brain derived neurotrophic factor, and decreasing GLI-3 protein, GFAP immune reaction in astrocytes, and inflammatory markers.
Article
Biochemistry & Molecular Biology
Radomir Juza, Kristyna Stefkova, Wim Dehaen, Alena Randakova, Tomas Petrasek, Iveta Vojtechova, Tereza Kobrlova, Lenka Pulkrabkova, Lubica Muckova, Marko Mecava, Lukas Prchal, Eva Mezeiova, Kamil Musilek, Ondrej Soukup, Jan Korabecny
Summary: In this pilot study, a series of new 3,4-dihydroquinolin-2(1H)-one derivatives were synthesized and evaluated as potential dopamine receptor D-2 (D2R) modulators. Compound 5e showed the highest D2R affinity among the synthesized compounds, with low cytotoxicity and high blood-brain barrier penetration probability. However, molecular modelling simulation revealed a different binding mode of 5e compared to USC-D301, possibly explaining the reduced affinity of 5e towards D2R.
Article
Medical Laboratory Technology
Minami Tasaki, Norio Yasui-Furukori, Kazuyoshi Kubo, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Yoshimasa Inoue, Kazutaka Shimoda
Summary: The study found that lower prolactin levels are associated with higher plasma drug concentrations in male and female patients with schizophrenia treated with aripiprazole.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Multidisciplinary Sciences
Maria A. Schumacher, Kelley A. Gallagher, Neil A. Holmes, Govind Chandra, Max Henderson, David T. Kysela, Richard G. Brennan, Mark J. Buttner
Summary: Filamentous actinobacteria of the genus Streptomyces have a complex lifecycle, which is regulated by c-di-GMP. The RsiG protein binds WhiG with different binding motifs. RsiG proteins from different origins show structural and functional differences, indicating a gene duplication event in evolutionary history.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Psychiatry
Chih-Min Liu, Chen -Chung Liu, Ming-Hsien Hsieh, Tzung-Jeng Hwang, Yi-Ting Lin, Yi-Ling Chien, Hai-Gwo Hwu
Summary: The plasma level of C4A decreased with aripiprazole treatment, and the decrease rate was associated with the treatment response of the positive dimension in patients with early psychosis.
PSYCHIATRY RESEARCH
(2022)
Article
Psychology, Clinical
Chiara Fabbri, Julian Mutz, Cathryn M. Lewis, Alessandro Serretti
Summary: This study was the first to comprehensively evaluate the predictors of wellbeing in relation to the history of MDD. The identified variables are important to identify individuals at risk and promote wellbeing.
PSYCHOLOGICAL MEDICINE
(2023)
Editorial Material
Neurosciences
Dekel Taliaz, Alessandro Serretti
Summary: The validity of clinical trials in psychiatry has been under discussion in the past two decades. The commonly used method of randomized controlled trials (RCTs) faces challenges when applied in the psychiatric field due to strict participant criteria and inconsistency in endpoint parameters. This has led to problematic clinical practice in psychiatry.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2023)
Article
Pharmacology & Pharmacy
Vincenzo Oliva, Giuseppe Fanelli, Manuel Zamparini, Cristina Zarbo, Matteo Rocchetti, Letizia Casiraghi, Fabrizio Starace, Alessandra Martinelli, Alessandro Serretti, Giovanni de Girolamo, DiAPASon Consortium
Summary: Antipsychotic polypharmacy (APP) is commonly used in patients with schizophrenia spectrum disorders (SSDs) despite recommendations against it. This study found high rates of APP and lower levels of physical activity in both residential and outpatient patients. However, patients on APP showed trends of reduced sedentariness and higher levels of light physical activity compared to those on monopharmacy.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Review
Psychiatry
Kristina Mozuraityte, Agne Stanyte, Naomi A. Fineberg, Alessandro Serretti, Julija Gecaite-Stonciene, Julius Burkauskas
Summary: This study conducted a scoping review of published literature to examine the relationship between mental fatigue and various psychiatric disorders. The findings suggest that mental fatigue is studied in mood disorders, anxiety disorders, obsessive-compulsive disorder, and obsessive-compulsive personality disorder. Cognitive factors such as unhelpful beliefs about sleep and symptom-focussed rumination, as well as personality risk factors, were found to be relevant in predicting mental fatigue symptoms. Further investigation is needed to explore mental fatigue in adult psychiatric samples.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
(2023)
Article
Psychiatry
Fabio Panariello, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri
Summary: This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression (TRD) patients. Results showed that the severity of depressive symptoms was associated with total, psychic, and neurological side effects, while autonomic side effects were higher in patients with somatic comorbidities and lower in patients receiving trazodone. Multivariate analyses revealed that depressive symptom severity was associated with psychic and total side effects, generalized anxiety disorder (GAD) with neurological side effects, and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e. increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2023)
Article
Pharmacology & Pharmacy
Laura Mandelli, Yuri Milaneschi, Sarah Hiles, Alessandro Serretti, Brenda W. Penninx
Summary: An unhealthy lifestyle plays a crucial role in the development and progression of chronic disorders, and it may also affect biological systems involved in stress response. Using data from the Netherlands Study of Depression and Anxiety, researchers calculated a global index of unhealthy lifestyle based on five self-reported habits. They found that the index was associated with hyperactivity of the hypothalamus-pituitary-adrenal axis and increased inflammation, indicating that unhealthy habits increase biological stress. The use of drugs also impacted the autonomic nervous system activity.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Chiara Fabbri, Alessandro Serretti
Summary: This study found that different clinical subtypes of major depressive disorder (MDD), particularly melancholic features and typical neurovegetative symptoms, may be associated with distinct underlying genetics. These findings contribute to a better understanding of the genetic heterogeneity of MDD.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Genetics & Heredity
Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, Chiara Fabbri, Alessandro Serretti
Summary: Nonpharmacological treatments for depression show effectiveness and tolerability in certain patients with diverse response. Genetic variables associated with treatment efficacy need to be examined to assist treatment selection. Most studies using candidate gene approach yielded poorly replicated findings due to small sample sizes, while a few methylome-wide and genome-wide association studies (GWASs) provided interesting results with the use of polygenic risk scores in small samples of electroconvulsive therapy (ECT) and cognitive-behavioral therapy. Further GWAS with larger sample sizes, such as the gen-ECT-ic consortium, can enhance our understanding of the genetic factors underlying treatment response in nonpharmacological therapies for depression.
PSYCHIATRIC GENETICS
(2023)
Editorial Material
Pharmacology & Pharmacy
Paolo Olgiati, Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Article
Chemistry, Analytical
Jaime Millan-Santiago, Rosalba Vitagliano, Fortunata Mondella, Roberto Mandrioli, Roccaldo Sardella, Rafael Lucena, Tomaz Vovk, Soledad Cardenas, Federico Boaron, Alessandro Serretti, Carmine Petio, Michele Protti, Laura Mercolini
Summary: In this study, a bioanalytical method using volumetric absorptive microsampling (VAMS) was developed and validated for therapeutic drug monitoring (TDM) of psychiatric patients under cariprazine treatment. The VAMS-UHPLC-MS methodology showed satisfactory results and was proven to be a useful alternative to cariprazine plasma analysis in clinical practice.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2023)
Review
Neurosciences
Alessandro Serretti
Summary: Anhedonia is a core symptom of depression and other psychiatric disorders, referring to a lack of pleasure or reward. It is not only a psychological distress but also encompasses a range of reward processing deficits. Anhedonia is a relevant risk factor for suicidal behaviors and may operate independently of the severity of depressive episodes. It has also been associated with inflammation, which can have a reciprocal detrimental effect on depression. The neurophysiological bases of anhedonia mainly involve changes in striatal and prefrontal areas, with dopamine playing a key role as the neurotransmitter involved. Anhedonia is believed to have a significant genetic component and polygenic risk scores may be a tool for predicting an individual's risk for developing anhedonia. Traditional antidepressants have shown limited benefit in treating anhedonia, also considering their potential to worsen anhedonia in some individuals. Other treatments such as agomelatine, vortioxetine, ketamine, and transcranial magnetic stimulation may be more effective. Psychotherapy, particularly cognitive-behavioral therapy and behavioral activation, is widely supported as beneficial for anhedonia. In conclusion, evidence suggests that anhedonia is partially independent from depression and requires careful evaluation and targeted treatment.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2023)
Article
Psychiatry
Alexander Kautzky, Lucie Bartova, Gernot Fugger, Markus Dold, Daniel Souery, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz, Chiara Fabbri, Alessandro Serretti, Dan Rujescu, Siegfried Kasper
Summary: This study investigates the differences in presentation and treatment outcomes of treatment-resistant depression (TRD) among different age groups. It finds that age has an impact on depressive symptoms and treatment outcomes. In TRD patients, symptom load and hospitalization time increase with age, while treatment responders do not show this trend. Older patients are more likely to have symptoms such as inner tension, reduced appetite, concentration difficulties, and lassitude.
EUROPEAN PSYCHIATRY
(2023)
Article
Clinical Neurology
Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns
Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2024)
